Zentalis Pharmaceuticals Inc. Common Stock (ZNTL)

About ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in sol…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

106

Website

www.zentalis.com/

Fundamentals

1-day range

$3.72$3.89

Market cap

$331.02M

P/E (trailing)

—

P/E (forward)

-2.11

EPS (trailing)

$-1.91

Dividend yield

—

Beta

1.93

Avg. volume

1.22M

Forecasts

9 analyst ratings

Zentalis Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ZNTL

  Zentalis Pharmaceuticals Inc. Common Stock

  $3.8

  ▼ 2.06%
  Market cap $331.02MP/E —
  $1.21$6.95
• VNDA

  Vanda Pharmaceuticals Inc. Common Stock

  $5.29

  ▼ 2.76%
  Market cap $314.51MP/E —
  $4.27$9.94
• UPB

  Upstream Bio Inc. Common Stock

  $6.68

  ▼ 1.62%
  Market cap $349.38MP/E —
  $5.85$33.68
• DMAC

  DiaMedica Therapeutics Inc. Common Stock

  $6.39

  ▼ 5.33%
  Market cap $351.32MP/E —
  $5.14$10.42
• ORGO

  Organogenesis Holdings Inc. Class A Common Stock

  $1.74

  ▼ 0.00%
  Market cap $301.10MP/E 84.95
  $1.54$7.08
• IRD

  Opus Genetics Inc. Common Stock

  $3.7

  ▼ 3.90%
  Market cap $300.54MP/E —
  $1.17$5.81
• RCKT

  Rocket Pharmaceuticals Inc. Common Stock

  $3.86

  ▲ 6.49%
  Market cap $372.35MP/E —
  $2.53$5.45

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
  Benzinga · 8/20/2026
• 12 Health Care Stocks Moving In Friday's Pre-Market Session
  Benzinga · 8/14/2026
• 12 Health Care Stocks Moving In Thursday's After-Market Session
  Benzinga · 8/13/2026
• Zentalis Pharmaceuticals Announces Proposed Public Offering Of Shares And Pre-Funded Warrants
  Benzinga · 8/13/2026

• Scott Dunseth Myers · June 16, 2026 · Grant

  57.1K
• Shannon Campbell · May 26, 2026 · Grant

  114.2K

Institutional Ownership

March 31, 2026

Total shares held

43.23M

Total value held

$92.70M

Institutional holders

97